CAMP4 THERAPEUTICS CORPORATION

CAMP · NasdaqGM

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

Growth

Health

–

Risk

–

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders9.7%

Institutions79.7%

Public / Other

Income Statement

	2025-12-31	2024-12-31	2023-02-28	2022-02-28	2021-02-28	2020-02-29	2019-02-28	2018-02-28	2017-02-28	2016-02-29
Total money the company brought in from its core business during the period, before any costs are subtracted.	$3.50M	$652000	$294.95M	$295.84M	$308.59M	$366.11M	$363.80M	$365.91M	$351.10M	$280.72M
The direct costs of producing what was sold — raw materials, manufacturing, direct labor.	–	–	$185.94M	$173.95M	$186.18M	$222.80M	$216.04M	$215.02M	$207.75M	$177.76M
Revenue left after subtracting the direct cost of producing goods or services — how efficiently the core business converts sales into profit before overhead.	–	–	$109.01M	$121.89M	$122.41M	$143.30M	$147.76M	$150.89M	$143.35M	$102.96M
Gross profit as a percentage of revenue.	–	–	37.0%	41.2%	39.7%	39.1%	40.6%	41.2%	40.8%	36.7%
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	-$52.55M	-$53.09M	-$24.68M	-$13.47M	-$6.83M	-$40.20M	$19.70M	$7.96M	$123000	$28.09M
Operating income as a percentage of revenue.	-1502.4%	-8142.3%	-8.4%	-4.6%	-2.2%	-11.0%	5.4%	2.2%	0.0%	10.0%
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	-$80.40M	-$51.79M	-$32.49M	-$27.99M	-$56.31M	-$79.30M	$18.40M	$16.62M	-$7.90M	$16.94M
Net income divided by the number of shares outstanding — profit attributable to each share.	$-2.65	$-11.04	–	–	–	$-2.00	$0.53	$0.00	$0.00	$0.00
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$-2.65	$-11.04	–	–	–	$-2.00	$0.52	$0.00	$0.00	$0.00

Balance Sheet

	2025-12-31	2024-12-31	2023-02-28	2022-02-28	2021-02-28	2020-02-29	2019-02-28	2018-02-28	2017-02-28	2016-02-29
Cash and highly liquid short-term investments the company can access almost immediately.	$109.52M	$64.04M	$41.93M	$79.22M	$94.62M	$107.40M	$256.50M	$132.60M	$93.71M	$139.39M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$117.81M	$78.31M	$380.12M	$391.58M	–	$495.81M	–	$472.99M	$408.14M	$384.36M
All of the company's interest-bearing borrowings, short and long term combined.	–	–	$228.12M	$192.29M	$186.47M	$210.21M	$275.90M	$154.30M	$146.83M	$139.80M
Everything the company owes — debt, unpaid bills, and other obligations.	$70.10M	$15.16M	$365.81M	$316.18M	–	$357.89M	–	$274.08M	$244.90M	$194.92M
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$47.70M	$63.14M	$14.31M	$75.40M	–	$137.92M	–	$198.92M	$163.24M	$189.45M

Cash Flow Statement

	2025-12-31	2024-12-31	2023-02-28	2022-02-28	2021-02-28	2020-02-29	2019-02-28	2018-02-28	2017-02-28	2016-02-29
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	-$29.60M	-$45.60M	-$22.93M	-$3.82M	$33.00M	$11.54M	$47.74M	$66.89M	$25.80M	$47.40M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$279000	$441000	$11.10M	$13.30M	$11.36M	$22.19M	$12.01M	$8.34M	$7.96M	$4.32M
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	-$29.88M	-$46.04M	-$34.03M	-$17.12M	$21.64M	-$10.65M	$35.73M	$58.55M	$17.83M	$43.08M

	You	Peer avg
Revenue Growth	+18.8%	+196.8%
ROE	-545.9%	-102.9%

CAMP4 THERAPEUTICS CORPORATION

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Income Statement

Balance Sheet

Cash Flow Statement

Peer Comparison